YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets t…
With Australian interest rates now at a 15-year high, cheap debt no longer does the heavy lifting for corporate performance. Investors are paying closer attention to who is actually steering each business. Founder led Australian companies,…
Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful…
Global bond yields are climbing, and central banks are tightening policy to keep inflation in check. That raises the bar for every listed company. Founder led Australian businesses can be different because leaders often have more of their…
Mesoblast Limited NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the Unite…
[Steelworker cleaning pouring end of flask during steel pour in steelworks] Monty Rakusen * Iron ore topped $100 a ton for the first time in seven weeks on Monday, driven by traders unwinding coking coal bets, anticipated pre-holiday resto…
Rising treasury and sovereign yields driven by persistent inflation concerns are forcing investors to think harder about where future growth might justify the extra risk. This is where fast-growing stocks with high insider ownership become…
Global debt markets are back in focus as the US 10 year yield hovers around the mid 4% range ahead of Jackson Hole. Higher yields can punish weaker balance sheets, yet they often highlight companies that still commit their own capital. Thi…
With central banks in several regions still pricing in tighter policy as they watch inflation and growth data, plenty of investors are looking down the market cap spectrum for ideas that do not rely on cheap money to work. That is where th…
Mesoblast Limited RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:ME…
Energy remains a wild card for inflation, with oil prices and broader energy costs still shaping central bank thinking. When policy can shift quickly, many investors look for something more anchored than quarterly guidance. Founder led com…
Central banks are weighing possible further rate hikes to keep inflation in check, which keeps pressure on weaker balance sheets and slower growth stories. Healthy high growth potential stocks can look more attractive in this kind of rate…
Mesoblast Limited NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and fin…
Mesoblast Limited NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in th…
Mesoblast Limited Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report for…
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report for Quarter Ended June…
NEW YORK, July 14, 2026--(BUSINESS WIRE)--Announcement of Mesabi Trust Distribution The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interest ("Unit"), payable on August 20, 2026…
Mesoblast Limited Continued Growth Underpins First Full Year Net Revenue of US$115M NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory disea…
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for…
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) fili…
Mesoblast Limited Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader…
In the midst of a challenging period for Australian shares, with market sentiment swayed by geopolitical tensions and economic uncertainties, investors are increasingly on the lookout for opportunities in undervalued stocks. Identifying st…
As Australian shares rebound from a significant market downturn, driven by global events and domestic fiscal policies, investors are keenly observing the landscape for opportunities. In this environment, growth companies with high insider…
Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or ne…
The Australian share market is experiencing a downturn, influenced by the recent budget announcement and external pressures such as rising U.S. inflation, which has caused some uncertainty among investors. In this environment, identifying…
NEW YORK, May 04, 2026--(BUSINESS WIRE)--Quarterly Royalty Report and Royalty Payment On April 30, 2026, the Trustees of Mesabi Trust (NYSE: MSB) received the quarterly royalty report of iron ore shipments from Silver Bay, Minnesota during…
Mesoblast Limited recently announced it has completed patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study following at least 300 patien…
Mesoblast Limited Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:…
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), gl…
As the Australian market faces its seventh consecutive day in the red, with inflation expected to spike to nearly three-year highs, investor sentiment has turned bearish. Despite these challenging conditions, penny stocks remain a relevant…
As Australian shares enter their seventh consecutive day in the red, market sentiment has shifted into bearish territory amid concerns over rising inflation and potential interest rate hikes. In this challenging environment, growth compani…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Mesoblast share move and recent return profile Mesoblast (ASX:MSB) recently closed at A$2.15, catching attention after…
Mesoblast Limited NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial eval…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Mesabi Trust’s decision to cut its distribution, after receiving lower royalty payments from Clev…
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a paten…
Mesoblast Limited NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide…